Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial吡啶斯的明降低严重SARS-CoV-2感染患者的死亡率: 一项2/3期随机对照试验MOLECULAR MEDICINEIF6.42022-11-087OAAI
A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocolBMC INFECTIOUS DISEASESIF32020-10-169OAAI
Nanoparticles administered intrapericardially enhance payload myocardial distribution and retention心内注射纳米颗粒可增强有效载荷心肌的分布和保留JOURNAL OF CONTROLLED RELEASEIF11.52017-09-0118OAAI
Rapamycin nanoparticles localize in diseased lung vasculature and prevent pulmonary arterial hypertension雷帕霉素纳米颗粒定位于患病的肺血管系统并预防肺动脉高压INTERNATIONAL JOURNAL OF PHARMACEUTICSIF5.22017-05-0132PREAI